Sientra (NSDQ:SIEN) last week closed a $115 million underwritten public offering, with plans to use the net proceeds to implement sales and marketing initiatives, as well as grow its U.S. and global commercial organizations. The medical aesthetics company offered 17,391,305 shares of its common stock and 2,608,695 additional shares of common stock in options to the […]
Sientra boosts offering to $100m
Sientra (NSDQ:SIEN) yesterday lifted the total it is looking to raise in an upcoming offering from a previously announced $75 million to $100 million. In the offering, which was announced earlier this week, the Santa Barbara, Calif.-based company said it plans to float approximately 17.4 million shares of its common stock at a price of $5.75 […]
Sientra plans $75m offering
Sientra (NSDQ:SIEN) yesterday announced an upcoming offering looking to raise approximately $75 million. In the offering, the Santa Barbara, Calif.-based company said it plans to offer $75 million in its common stock to help support sales and marketing initiatives, to expand its U.S. and global commercial teams and to fund research and development efforts. Sientra added […]
Sientra plunges on Q1 results
Sientra (NSDQ:SIEN) shares plunged today after the cosmetic device maker’s first-quarter earnings missed the mark by a mile. Losses grew 36.4% for Santa Barbara, Calif.-based Sientra, to -$26.5 million, or -91¢ per share, on sales growth of 19.6% to $17.6 million during the three months ended March 31, compared with Q1 2018. Analysts on Wall […]
FDA won’t ban textured breast implants
The FDA yesterday said it won’t ban textured breast implants, which may be linked to a type of immune system cancer, after one of its advisory panels said there’s not enough evidence to support the move. In March the federal safety watchdog’s General & Plastic Surgery Devices panel held two days of hearings before reaching […]
FDA warns J&J, Sientra over lack of post-approval silicone gel breast implant studies
The FDA today released warning letters it sent to Johnson & Johnson (NYSE:JNJ) subsidiary Mentor Worldwide and Sientra (NSDQ:SIEN) over failures to conduct appropriate post-approval studies to analyze the long-term safety and risks associated with their silicone gel-filled breast implants. The federal watchdog said that every manufacturer of approved silicone gel-filled breast implants is required to conduct […]
Sientra plunges on Q4 earnings miss, clouded outlook
A fourth-quarter earnings miss and the uncertainty around an upcoming FDA advisory panel meeting on breast implants sent Sientra (NSDQ:SIEN) shares down precipitously today. The Santa Barbara, Calif.-based medical aesthetics company’s losses widened 38.1% to -$24.6 million, or 86¢ per share, on sales growth of 71.9% to $19.0 million for the three months ended Dec. […]
AtriCure falls despite solid Q4, 2018 prelims | Wall Street Beat
AtriCure (NSDQ:ATRC) shares took a fall today despite preliminary results for the fourth quarter and 2018 that topped estimates. The Mason, Ohio-based cardiac implant maker said it expects to post Q4 sales of $52.9 million and 2018 sales of $201.6 million, beating the consensus estimatyes on Wall Street for both periods. “We are pleased with our […]
SEC accuses ex-Sientra CEO Zeini of lying to investors ahead of $60m offering
The U.S. Securities & Exchange Commission today accused former Sientra (NSDQ:SIEN) CEO Hani Zeini of hiding a problem at the company to close a $61 million follow-on offering that led to the company losing more than half of its value. The breast implant maker relied on a single supplier for its silicone implants. But regulators in […]
FDA OKs Opus breast implant line from Sientra
The FDA this week granted a pre-market approval supplement to Sientra (NSDQ:SIEN) for its Opus line of silicone breast implants. The implants are made in Wisconsin by Lubrizol LifeSciences subsidiary Vesta, which inked a contract manufacturing deal with Sientra back in August 2016. Sales of Sientra’s silicone breast implants ground to a halt in the autumn of 2015, when […]
Sientra inks contract manufacturing deal with Lubrizol’s Vesta
Sientra (NSDQ:SIEN) said today that it inked a contract manufacturing deal for its breast implants with Lubrizol LifeSciences subsidiary Vesta. Santa Barbara, Calif.-based Sientra was off the market for 4 months after Brazilian regulators shut down production last year at its sole supplier. The company, which was back on the market March 1, was stymied […]
MassDevice Network
@MassDevice
LinkedIn
YouTube